BIOCRYST PHARMACEUTICALS INC (BCRX)

Data as of Sep 2, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch BCRX

See up to 3 months of BCRX. The 7-day demo opens the 1M and 3M ranges and puts BCRX on your watchlist.

Latest BCRX insider trades

Amy E. McKee - Director
Open-market sale$100K
May 18, 2026
Alane P. Barnes - Officer
Open-market sale$596K
May 13, 2026
Theresa Heggie - Director

About BIOCRYST PHARMACEUTICALS INC (BCRX)

BIOCRYST PHARMACEUTICALS INC files with the SEC under CIK 0000882796 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for BCRX on EDGAR

BCRX Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Grant or award	5	5,023

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

BCRX insider transactions (Form 4)

65 Form 4 filings on record, the earliest from Dec 2, 2024, newest first. Filing history page 1 of 3.

Date	Insider	Transaction	Security	Shares	Price	Value
Aug 31, 2026	Jon P. Stonehouse - Director	Grant or award	Common Stock	644^{footnote F1}	$9.70	$6K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.
Aug 31, 2026	Jill C. Milne - Director	Grant or award	Common Stock	1,288^{footnote F1}	$9.70	$12K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.
Aug 31, 2026	Vincent Milano - Director	Grant or award	Common Stock	1,159^{footnote F1}	$9.70	$11K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.
Aug 31, 2026	Amy E. McKee - Director	Grant or award	Common Stock	644^{footnote F1}	$9.70	$6K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.
Aug 31, 2026	Steven Frank - Director	Grant or award	Common Stock	1,288^{footnote F1}	$9.70	$12K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.
Jun 11, 2026	Jill C. Milne - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Jun 11, 2026	Jill C. Milne - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Steven K. Galson - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Jun 11, 2026	Steven K. Galson - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Alan G. Levin - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Jun 11, 2026	Alan G. Levin - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Steven Frank - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Jun 11, 2026	Steven Frank - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Machelle Sanders - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Jun 11, 2026	Machelle Sanders - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Vincent Milano - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Jun 11, 2026	Vincent Milano - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Jon P. Stonehouse - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Jun 11, 2026	Jon P. Stonehouse - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Amy E. McKee - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Jun 11, 2026	Amy E. McKee - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Jun 11, 2026	Theresa Heggie - Director	Grant or award	Automatic Stock Option Grant	33,540	$0.00	-
Jun 11, 2026	Theresa Heggie - Director	Grant or award	Common Stock	15,294^{footnote F1}	$0.00	-
Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
May 29, 2026	Jill C. Milne - Director	Grant or award	Common Stock	1,262^{footnote F1}	$8.91	$11K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.
May 29, 2026	Jon P. Stonehouse - Director	Grant or award	Common Stock	631^{footnote F1}	$8.91	$6K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.
May 29, 2026	Amy E. McKee - Director	Grant or award	Common Stock	631^{footnote F1}	$8.91	$6K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.
May 29, 2026	Vincent Milano - Director	Grant or award	Common Stock	1,122^{footnote F1}	$8.91	$10K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.
May 29, 2026	Steven Frank - Director	Grant or award	Common Stock	1,262^{footnote F1}	$8.91	$11K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.
May 18, 2026	Amy E. McKee - Director	Open-market sale	Common Stock	11,180	$8.97^{footnote F1}	$100K
Footnote F1 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.96 to $8.985. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR
May 13, 2026	Alane P. Barnes - Officer	Option exercise	Common Stock	62,500^{footnote F1}	$5.04	$315K
May 13, 2026	Alane P. Barnes - Officer	Open-market sale	Common Stock	62,500^{footnote F1}	$9.54	$596K
May 13, 2026	Alane P. Barnes - Officer	Option exercise	Emp. Stock Option (Right to Buy)	62,500^{footnote F1}	$0.00	-
Footnote F1 (shares): This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the… Full note on SEC EDGAR
Apr 6, 2026	Sandeep Menon - Officer	Grant or award	Common Stock	205,150^{footnote F1}	$0.00	-
Apr 6, 2026	Sandeep Menon - Officer	Grant or award	Emp. Stock Option (Right to Buy)	441,350^{footnote F2}	$0.00	-
Footnote F1 (shares): Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Footnote F2 (shares): Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Mar 20, 2026	Theresa Heggie - Director	Option exercise	Common Stock	49,933	$6.30	$315K
Mar 20, 2026	Theresa Heggie - Director	Option exercise	Automatic Stock Option Grant	49,933	$0.00	-
Mar 20, 2026	Theresa Heggie - Director	Open-market sale	Common Stock	49,933	$10.11^{footnote F1}	$505K
Footnote F1 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.09 to $10.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR
Mar 16, 2026	Alane P. Barnes - Officer	Option exercise	Common Stock	150,000^{footnote F1}	$5.51	$827K
Mar 16, 2026	Alane P. Barnes - Officer	Open-market sale	Common Stock	150,000^{footnote F1}	$9.15^{footnote F2}	$1.37M
Mar 16, 2026	Alane P. Barnes - Officer	Option exercise	Emp. Stock Option (Right to Buy)	150,000^{footnote F1}	$0.00	-
Footnote F1 (shares): This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the… Full note on SEC EDGAR Footnote F2 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR
Feb 27, 2026	Jill C. Milne - Director	Grant or award	Common Stock	528^{footnote F1}	$8.75	$5K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the prorated quarterly cash Board Member retainer of $4,625.
Feb 27, 2026	Jon P. Stonehouse - Director	Grant or award	Common Stock	421^{footnote F1}	$8.75	$4K
Mar 2, 2026	Jon P. Stonehouse - Director	Option exercise	Common Stock	305,995^{footnote F2}	$3.22	$985K
Mar 2, 2026	Jon P. Stonehouse - Director	Derivative	Common Stock	305,995^{footnote F2}	$8.64^{footnote F3}	$2.64M
Mar 2, 2026	Jon P. Stonehouse - Director	Option exercise	Emp. Stock Option (Right to Buy)	305,995^{footnote F2}	$0.00	-
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375. Footnote F2 (shares): This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally… Full note on SEC EDGAR Footnote F3 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR
Feb 27, 2026	Vincent Milano - Director	Grant or award	Common Stock	848^{footnote F1}	$8.75	$7K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.
Feb 27, 2026	Steven Frank - Director	Grant or award	Common Stock	1,285^{footnote F1}	$8.75	$11K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.
Feb 27, 2026	Amy E. McKee - Director	Grant or award	Common Stock	642^{footnote F1}	$8.75	$6K
Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.
Jan 23, 2026	Jill C. Milne - Director	Grant or award	Common Stock	2,582	-^{footnote F1}	-
Jan 23, 2026	Jill C. Milne - Director	Grant or award	Common Stock	12,272^{footnote F2}	$0.00	-
Jan 23, 2026	Jill C. Milne - Director	Grant or award	Automatic Stock Option Grant	26,684	$0.00	-
Footnote F1 (price): Received in exchange for 4,377 shares of Astria Therapeutics, Inc. ("Astria") common stock in connection with a merger (the "Merger"), pursuant to which Astria became a wholly owned subsidiary of BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Merger, each share of… Full note on SEC EDGAR Footnote F2 (shares): Automatic non-employee director grant of restricted stock units pursuant to the BioCryst Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest in three equal annual installments beginning on the twelve-month anniversary of… Full note on SEC EDGAR

Recent BCRX Form 8-K filings

Read BCRX company news

Aug 5, 2026Item 2.02, 7.01, 9.01

Read the filing on SEC EDGAR

Aug 4, 2026Item 2.05

Read the filing on SEC EDGAR

Jun 29, 2026Item 2.05, 7.01, 9.01

Read the filing on SEC EDGAR

Jun 12, 2026Item 5.02, 5.07, 9.01

Recent BCRX Form 144 notices of proposed sale

An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.

Filed	Filer	Relationship	Shares	Market value	Notice
May 18, 2026	-	-	-	-	View on EDGAR
May 13, 2026	-	-	-	-

Congress trades in BCRX

All congress trades

Stock trades in BCRX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.

Member	Type	Traded	Disclosed	Value range	Owner	Days to disclose	Filing
Gilbert Ray Cisneros, Jr.Democrat, CA-31	Purchase

BCRX insider trading FAQ

What is the latest insider trade for BCRX?

BIOCRYST PHARMACEUTICALS INC (BCRX) had 5 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for BCRX runs to 65 Form 4 filings, the earliest from 2024-12-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying BCRX stock?

No insider purchases of BCRX were filed in the last 90 days.

How many insiders are selling BCRX stock?

No insider sales of BCRX were filed in the last 90 days. 12 sales are on record for this company.

Where can I see BCRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects BCRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Sep 2, 2026 - Jon P. Stonehouse view on EDGAR
Sep 2, 2026 - Jill C. Milne view on EDGAR
Sep 2, 2026 - Vincent Milano view on EDGAR
Sep 2, 2026 - Amy E. McKee view on EDGAR
Sep 2, 2026 - Steven Frank view on EDGAR
Jun 15, 2026 - Jill C. Milne view on EDGAR
Jun 15, 2026 - Steven K. Galson view on EDGAR
Jun 15, 2026 - Alan G. Levin view on EDGAR
Jun 15, 2026 - Steven Frank view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Form 144 vs Form 4: A Form 144 announces a planned sale; the Form 4 reports it after it happens.
Insider activity in Health Care: Where BCRX's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow BCRX with a 7-day demo

BCRX on your watchlist
Every BCRX Form 4 filing on record
Up to 3 months of BCRX price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Grant or award

5,023

Date

Insider

Transaction

Security

Price

Value

Aug 31, 2026

Jon P. Stonehouse - Director

Grant or award

Common Stock

644^{footnote F1}

$9.70

$6K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

Aug 31, 2026

Jill C. Milne - Director

Grant or award

Common Stock

1,288^{footnote F1}

$9.70

$12K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

Aug 31, 2026

Vincent Milano - Director

Grant or award

Common Stock

1,159^{footnote F1}

$9.70

$11K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $22,500.

Aug 31, 2026

Amy E. McKee - Director

Grant or award

Common Stock

644^{footnote F1}

$9.70

$6K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.

Aug 31, 2026

Steven Frank - Director

Grant or award

Common Stock

1,288^{footnote F1}

$9.70

$12K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

Jun 11, 2026

Jill C. Milne - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Jun 11, 2026

Jill C. Milne - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Steven K. Galson - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Jun 11, 2026

Steven K. Galson - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Alan G. Levin - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Jun 11, 2026

Alan G. Levin - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Steven Frank - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Jun 11, 2026

Steven Frank - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Machelle Sanders - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Jun 11, 2026

Machelle Sanders - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Vincent Milano - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Jun 11, 2026

Vincent Milano - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Jon P. Stonehouse - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Jun 11, 2026

Jon P. Stonehouse - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Amy E. McKee - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Jun 11, 2026

Amy E. McKee - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Jun 11, 2026

Theresa Heggie - Director

Grant or award

Automatic Stock Option Grant

33,540

$0.00

Jun 11, 2026

Theresa Heggie - Director

Grant or award

Common Stock

15,294^{footnote F1}

$0.00

Footnote F1 (shares): Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

May 29, 2026

Jill C. Milne - Director

Grant or award

Common Stock

1,262^{footnote F1}

$8.91

$11K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

May 29, 2026

Jon P. Stonehouse - Director

Grant or award

Common Stock

631^{footnote F1}

$8.91

$6K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

May 29, 2026

Amy E. McKee - Director

Grant or award

Common Stock

631^{footnote F1}

$8.91

$6K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

May 29, 2026

Vincent Milano - Director

Grant or award

Common Stock

1,122^{footnote F1}

$8.91

$10K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.

May 29, 2026

Steven Frank - Director

Grant or award

Common Stock

1,262^{footnote F1}

$8.91

$11K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

May 18, 2026

Amy E. McKee - Director

Open-market sale

Common Stock

11,180

$8.97^{footnote F1}

$100K

Footnote F1 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.96 to $8.985. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR

May 13, 2026

Alane P. Barnes - Officer

Option exercise

Common Stock

62,500^{footnote F1}

$5.04

$315K

May 13, 2026

Alane P. Barnes - Officer

Open-market sale

Common Stock

62,500^{footnote F1}

$9.54

$596K

May 13, 2026

Alane P. Barnes - Officer

Option exercise

Emp. Stock Option (Right to Buy)

62,500^{footnote F1}

$0.00

Footnote F1 (shares): This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the… Full note on SEC EDGAR

Apr 6, 2026

Sandeep Menon - Officer

Grant or award

Common Stock

205,150^{footnote F1}

$0.00

Apr 6, 2026

Sandeep Menon - Officer

Grant or award

Emp. Stock Option (Right to Buy)

441,350^{footnote F2}

$0.00

Footnote F1 (shares): Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Footnote F2 (shares): Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Mar 20, 2026

Theresa Heggie - Director

Option exercise

Common Stock

49,933

$6.30

$315K

Mar 20, 2026

Theresa Heggie - Director

Option exercise

Automatic Stock Option Grant

49,933

$0.00

Mar 20, 2026

Theresa Heggie - Director

Open-market sale

Common Stock

49,933

$10.11^{footnote F1}

$505K

Footnote F1 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.09 to $10.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR

Mar 16, 2026

Alane P. Barnes - Officer

Option exercise

Common Stock

150,000^{footnote F1}

$5.51

$827K

Mar 16, 2026

Alane P. Barnes - Officer

Open-market sale

Common Stock

150,000^{footnote F1}

$9.15^{footnote F2}

$1.37M

Mar 16, 2026

Alane P. Barnes - Officer

Option exercise

Emp. Stock Option (Right to Buy)

150,000^{footnote F1}

$0.00

Footnote F1 (shares): This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the… Full note on SEC EDGAR
Footnote F2 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.95 to $9.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR

Feb 27, 2026

Jill C. Milne - Director

Grant or award

Common Stock

528^{footnote F1}

$8.75

$5K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the prorated quarterly cash Board Member retainer of $4,625.

Feb 27, 2026

Jon P. Stonehouse - Director

Grant or award

Common Stock

421^{footnote F1}

$8.75

$4K

Mar 2, 2026

Jon P. Stonehouse - Director

Option exercise

Common Stock

305,995^{footnote F2}

$3.22

$985K

Mar 2, 2026

Jon P. Stonehouse - Director

Derivative

Common Stock

305,995^{footnote F2}

$8.64^{footnote F3}

$2.64M

Mar 2, 2026

Jon P. Stonehouse - Director

Option exercise

Emp. Stock Option (Right to Buy)

305,995^{footnote F2}

$0.00

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375.
Footnote F2 (shares): This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally… Full note on SEC EDGAR
Footnote F3 (price): The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the… Full note on SEC EDGAR

Feb 27, 2026

Vincent Milano - Director

Grant or award

Common Stock

848^{footnote F1}

$8.75

$7K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000.

Feb 27, 2026

Steven Frank - Director

Grant or award

Common Stock

1,285^{footnote F1}

$8.75

$11K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $11,250.

Feb 27, 2026

Amy E. McKee - Director

Grant or award

Common Stock

642^{footnote F1}

$8.75

$6K

Footnote F1 (shares): Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

Jan 23, 2026

Jill C. Milne - Director

Grant or award

Common Stock

2,582

-^{footnote F1}

Jan 23, 2026

Jill C. Milne - Director

Grant or award

Common Stock

12,272^{footnote F2}

$0.00

Jan 23, 2026

Jill C. Milne - Director

Grant or award

Automatic Stock Option Grant

26,684

$0.00

Footnote F1 (price): Received in exchange for 4,377 shares of Astria Therapeutics, Inc. ("Astria") common stock in connection with a merger (the "Merger"), pursuant to which Astria became a wholly owned subsidiary of BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Merger, each share of… Full note on SEC EDGAR
Footnote F2 (shares): Automatic non-employee director grant of restricted stock units pursuant to the BioCryst Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest in three equal annual installments beginning on the twelve-month anniversary of… Full note on SEC EDGAR

Filed

Filer

Relationship

Market value

Notice

May 18, 2026

View on EDGAR

May 13, 2026

Member	Type	Traded	Disclosed	Value range	Owner	Days to disclose	Filing
Gilbert Ray Cisneros, Jr.Democrat, CA-31	Purchase

Member

Type

Traded

Disclosed

Value range

Owner

Days to disclose

Filing

Gilbert Ray Cisneros, Jr.Democrat, CA-31

Purchase